BR112014023414A2 - vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos - Google Patents

vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos

Info

Publication number
BR112014023414A2
BR112014023414A2 BR112014023414A BR112014023414A BR112014023414A2 BR 112014023414 A2 BR112014023414 A2 BR 112014023414A2 BR 112014023414 A BR112014023414 A BR 112014023414A BR 112014023414 A BR112014023414 A BR 112014023414A BR 112014023414 A2 BR112014023414 A2 BR 112014023414A2
Authority
BR
Brazil
Prior art keywords
equine herpesvirus
vaccine containing
recombinant
recombinant equine
mutant glycoprotein
Prior art date
Application number
BR112014023414A
Other languages
English (en)
Other versions
BR112014023414A8 (pt
BR112014023414B1 (pt
Inventor
Ma Guanggang
Audonnet Jean-Christophe
Maarten Minke Jules
Osterrieder Nikolaus
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BR112014023414A2 publication Critical patent/BR112014023414A2/pt
Publication of BR112014023414A8 publication Critical patent/BR112014023414A8/pt
Publication of BR112014023414B1 publication Critical patent/BR112014023414B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16762—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo da patente de invenção para: ”vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos”. a presente invenção fornece composições ou vacinas que contêm um ehv-1 recombinante que desencadeiam uma resposta imune em animais contra o herpesvírus equino, incluindo composições compreendendo os referidos ehv-1 recombinantes, os métodos de vacinação contra o herpesvirus equino, e kits para uso em tais métodos e composições
BR112014023414-0A 2012-03-20 2013-03-15 Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos BR112014023414B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613151P 2012-03-20 2012-03-20
US61/613,151 2012-03-20
PCT/US2013/032491 WO2013142371A1 (en) 2012-03-20 2013-03-15 Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof

Publications (3)

Publication Number Publication Date
BR112014023414A2 true BR112014023414A2 (pt) 2017-07-11
BR112014023414A8 BR112014023414A8 (pt) 2022-07-05
BR112014023414B1 BR112014023414B1 (pt) 2022-08-30

Family

ID=48193269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023414-0A BR112014023414B1 (pt) 2012-03-20 2013-03-15 Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos

Country Status (16)

Country Link
US (2) US8916371B2 (pt)
EP (1) EP2827897B1 (pt)
JP (1) JP6201166B2 (pt)
CN (1) CN104302319B (pt)
AR (2) AR090450A1 (pt)
AU (1) AU2013235423B2 (pt)
BR (1) BR112014023414B1 (pt)
CA (1) CA2867893C (pt)
ES (1) ES2711878T3 (pt)
HK (1) HK1201205A1 (pt)
HU (1) HUE042396T2 (pt)
MX (1) MX355443B (pt)
NZ (1) NZ700470A (pt)
SG (1) SG11201405847SA (pt)
UY (1) UY34695A (pt)
WO (1) WO2013142371A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2760004T3 (es) * 2008-05-08 2020-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra Leishmania utilizando un inmunnógeno salival de mosca de la arena
US20130195918A1 (en) * 2011-08-08 2013-08-01 Dennis J. O'Callaghan Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof
WO2015073507A1 (en) * 2013-11-13 2015-05-21 Cornell University Stimulation of neonatal immunity
US10010594B2 (en) 2014-02-11 2018-07-03 University Of Miami Methods and compositions for transgene expression in a herpesvirus vector system
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
RU2736472C2 (ru) * 2016-11-18 2020-11-17 Общество с ограниченной ответственностью "ЭКСИФАРМ" Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк
WO2018119518A1 (en) 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
US11084272B2 (en) 2017-05-31 2021-08-10 General Electric Company Test structure for additive manufacture and related method for emitter alignment

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
DK175363B1 (da) 1986-09-12 2004-09-13 Genentech Inc Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69417717T2 (de) * 1993-12-20 1999-10-07 Akzo Nobel N.V., Arnheim/Arnhem Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
GB9625968D0 (en) * 1996-12-13 1997-01-29 Univ Glasgow Vaccine
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
DK1221955T3 (da) 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1317481A2 (en) * 2000-07-27 2003-06-11 Research Corporation Technologies, Inc Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
DE10116594A1 (de) * 2001-04-03 2002-10-10 Boehringer Ingelheim Vetmed Künstliche Chromosomen, die EHV-Sequenzen umfassen
US20030059934A1 (en) * 2001-04-03 2003-03-27 Nikolaus Osterrieder Artificial chromosomes comprising EHV sequences
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003062374A2 (en) 2001-11-09 2003-07-31 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
WO2004011677A2 (en) * 2002-07-26 2004-02-05 Animal Health Trust Viral marker
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
RS52705B (en) 2004-06-04 2013-08-30 Merial Limited Administration of FeLV Vaccine Without Needle
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines

Also Published As

Publication number Publication date
AR090450A1 (es) 2014-11-12
US9555101B2 (en) 2017-01-31
JP2015512395A (ja) 2015-04-27
MX355443B (es) 2018-04-18
AU2013235423B2 (en) 2017-03-30
US20130251747A1 (en) 2013-09-26
EP2827897B1 (en) 2018-10-31
ES2711878T3 (es) 2019-05-08
CN104302319B (zh) 2016-08-24
WO2013142371A1 (en) 2013-09-26
BR112014023414A8 (pt) 2022-07-05
CA2867893A1 (en) 2013-09-26
BR112014023414B1 (pt) 2022-08-30
HUE042396T2 (hu) 2019-06-28
US20150190502A1 (en) 2015-07-09
NZ700470A (en) 2016-04-29
HK1201205A1 (en) 2015-08-28
CA2867893C (en) 2022-09-20
JP6201166B2 (ja) 2017-09-27
AU2013235423A1 (en) 2014-10-16
AR124928A2 (es) 2023-05-17
MX2014011281A (es) 2015-05-11
CN104302319A (zh) 2015-01-21
US8916371B2 (en) 2014-12-23
EP2827897A1 (en) 2015-01-28
SG11201405847SA (en) 2014-10-30
UY34695A (es) 2013-10-31

Similar Documents

Publication Publication Date Title
BR112014023414A2 (pt) vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
BR112018000862A2 (pt) composições de vacina
MX2020007675A (es) Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
BR112016015422A2 (pt) formulações de vacina de frasco único
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
WO2014074817A3 (en) Attenuated mannheimia haemolytica vaccines and methods of making and use
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
BR112015018330A2 (pt) cepas de flavobacterium vivas modificadas, vacinas estabilizadas compreendendo as mesmas, e métodos de preparo e uso das mesmas
WO2013173256A3 (en) New and improved influenza vaccines

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MERIAL LIMITED (US)

B25A Requested transfer of rights approved

Owner name: MERIAL, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2013, OBSERVADAS AS CONDICOES LEGAIS